Profile data is unavailable for this security.
About the company
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.
- Revenue in USD (TTM)0.00
- Net income in USD-11.38m
- Incorporated1992
- Employees15.00
- LocationWindtree Therapeutics Inc2600 Kelly Rd Ste 100WARRINGTON 18976-3652United StatesUSA
- Phone+1 (215) 488-9300
- Fax+1 (215) 488-9301
- Websitehttps://windtreetx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Palisade Bio Inc | 0.00 | -14.17m | 4.45m | 9.00 | -- | 0.3653 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
Oncternal Therapeutics Inc | 1.85m | -35.97m | 4.53m | 27.00 | -- | 0.2875 | -- | 2.45 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
Qualigen Therapeutics Inc | 0.00 | -9.27m | 4.57m | 4.00 | -- | -- | -- | -- | -1.66 | -1.75 | 0.00 | -0.445 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
CNS Pharmaceuticals Inc | 0.00 | -15.97m | 4.60m | 3.00 | -- | -- | -- | -- | -134.04 | -134.04 | 0.00 | -2.97 | 0.00 | -- | -- | 0.00 | -358.12 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
Pasithea Therapeutics Corp | 0.00 | -16.37m | 4.61m | 8.00 | -- | 0.2853 | -- | -- | -14.98 | -14.99 | 0.00 | 15.49 | 0.00 | -- | -- | 0.00 | -58.66 | -- | -62.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
Chromocell Therapeutics Corp | 0.00 | -8.98m | 4.90m | 4.00 | -- | 4.34 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
ProtoKinetix, Inc. | 0.00 | -369.97k | 4.91m | 0.00 | -- | 12.10 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
Clearmind Medicine Inc | 0.00 | -8.44m | 4.91m | -- | -- | 1.39 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
Cingulate Inc | 0.00 | -19.10m | 4.94m | 13.00 | -- | 1.32 | -- | -- | -141.60 | -141.60 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -368.85 | -- | -- | -- | -- | -- | -- | -- | -- | -47.38 | 0.0042 | -- | -- | -- | -33.14 | -- | -- | -- |
Biostax Corp | 0.00 | -1.51m | 5.02m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
Windtree Therapeutics Inc | 0.00 | -11.38m | 5.04m | 15.00 | -- | 0.5303 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
Weed Inc | 0.00 | 57.30k | 5.31m | 2.00 | 84.31 | 706.08 | 61.40 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Burzynski Research Institute Inc | 0.00 | -1.42m | 5.40m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
Virios Therapeutics Inc | 0.00 | -5.30m | 5.53m | 4.00 | -- | 1.76 | -- | -- | -0.2603 | -0.2603 | 0.00 | 0.113 | 0.00 | -- | -- | 0.00 | -119.71 | -79.80 | -135.31 | -89.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.76 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Tower Research Capital LLCas of 30 Jun 2024 | 1.51k | 0.25% |
Bank of America, NA (Private Banking)as of 30 Jun 2024 | 4.00 | 0.00% |
UBS Financial Services, Inc.as of 30 Jun 2024 | 3.00 | 0.00% |
IFP Advisors, Inc.as of 30 Jun 2024 | 2.00 | 0.00% |
Activest Wealth Management LLCas of 30 Jun 2024 | 2.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
Geode Capital Management LLCas of 30 Jun 2024 | 0.00 | 0.00% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
Citadel Securities LLCas of 30 Jun 2024 | 0.00 | 0.00% |